Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456270 | 0.70 | L3MBTL1 (0.47) | POLBSLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL4199016 | 0.69 | CHRM1 (0.37) | POLBNPC1RAB9ALTA4HMEN1 | |
| SCHEMBL4199012 | 0.69 | CHRM1 (0.37) | POLBNPC1RAB9ALTA4HMEN1 | |
| SCHEMBL4195895 | 0.69 | ALDH1A1 (0.39) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL27805387 | 0.69 | ALDH1A1 (0.39) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL4195898 | 0.69 | ALDH1A1 (0.39) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL21790575 | 0.67 | MEN1 (0.53) | POLBSLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL4488511 | 0.67 | MIF (0.50) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13943897 | 0.66 | GHSR (0.39) | SLC6A2SLC6A4SLC6A3LTA4H | |
| SCHEMBL3650809 | 0.66 | GHSR (0.39) | SLC6A2SLC6A4SLC6A3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | claimed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | POLB 2794/4885SLC6A2 108/4885SLC6A4 160/4885 |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | POLB 2794/4885SLC6A2 108/4885SLC6A4 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.